The Global First ETa-specific Monoclonal Antibody GMA131 was Approved by the US FDA for the Clinical Study of Diabetic Kidney Disease

DKD, as the leading cause of chronic kidney disease and end stage renal disease (ESRD), is one of the most important complications of diabetes. 

GMAX's GMA106, second generation obesity/T2DM/NASH mAb gives first in human does.

It can be a significant breakthrough as the second generation of drugs in our developmental pipeline for the treatment of obesity and T2DM. 

GMAX Biopharm International raises USD 78M funding

The financing will help revamp our clinical trials and develop pipeline candidates to produce more innovative medicines for global patients in a much faster speed.

GMAX Zhengzhou Manufacturing Site Breaks Ground

Gmax Biopharm today holds ground-breaking ceremony for its Zhengzhou, China manufacturing site which is the production base for its GMA102 (T2D), GMA105 (obesity), and GMA301A/B (PAH for adult and children) drugs to be launched between 2023-2025, upon approval of respective clinical trials.

GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial

Hangzhou, China. Gmax Biopharm today announces that the first dose of GMA301 was given to the patient in its phase 1B trial to investigate the drug efficacy to treat pulmonary arterial hypertension (PAH).